4HAB image
Entry Detail
PDB ID:
4HAB
Title:
Crystal structure of Plk1 Polo-box domain in complex with PL-49
Biological Source:
Host Organism:
PDB Version:
Deposition Date:
2012-09-26
Release Date:
2013-04-03
Method Details:
Experimental Method:
Resolution:
2.65 Å
R-Value Free:
0.25
R-Value Work:
0.26
R-Value Observed:
0.26
Space Group:
P 43 21 2
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:Serine/threonine-protein kinase PLK1
Chain IDs:A, B, C
Chain Length:223
Number of Molecules:3
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Description:PL-49
Chain IDs:D, E, F
Chain Length:7
Number of Molecules:3
Biological Source:synthetic construct
Modified Residue
Compound ID Chain ID Parent Comp ID Details 2D Image
11Q D PRO 1-(CYCLOHEXYLMETHYL)-L-PROLINE
TPO D THR PHOSPHOTHREONINE
Peptide-like Molecules
PRD_000780
Primary Citation
Development of cyclic peptomer inhibitors targeting the polo-box domain of polo-like kinase 1.
Bioorg.Med.Chem. 21 2623 2634 (2013)
PMID: 23498919 DOI: 10.1016/j.bmc.2013.02.020

Abstact

The polo-box domain (PBD) of polo-like kinase 1 (Plk1) is essentially required for the function of Plk1 in cell proliferation. The availability of the phosphopeptide-binding pocket on PBD provides a unique opportunity to develop novel protein-protein interaction inhibitors. Recent identification of a minimal 5-residue-long phosphopeptide, PLHSpT, as a Plk1 PBD-specific ligand has led to the development of several peptide-based inhibitors, but none of them is cyclic peptide. Through the combination of single-peptoid mimics and thio-ether bridged cyclization, we successfully demonstrated for the first time two cyclic peptomers, PL-116 and PL-120, dramatically improved the binding affinity without losing mono-specificity against Plk1 PBD in comparison with the linear parental peptide, PLHSpT. These cyclic peptomers could serve as promising templates for future drug designs to inhibit Plk1 PBD.

Legend

Protein

Chemical

Disease

Primary Citation of related structures